Keywords: Eisai, fycompa, Supernus, Oxtellar XR, USA, FDA, Epilepsy

FDA approves Eisai's Fycompa to treat epileptic seizures and Supernus' Oxtellar XR

Article | 23 October 2012

Print This

The US Food and Drug Administration yesterday approved Japanese drug major Eisai’s (TYO: 4523) Fycompa (perampanel) tablets to treat ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in